GlassScriptPhysician profile
Stephanie L Larson
NPI 1295134385
$2,892.71
in general payments reported to CMS, 2019-2025
30 companies · $205 in 2025
The $205 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $851 · 2020: $291 · 2021: $585 · 2022: $424 · 2023: $294 · 2024: $244 · 2025: $205.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $710 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $709.66 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $515.81 | 2019-2024 | |
| Glaxosmithkline, LLC. | $413.67 | 2019-2025 | Bexsero |
| Novo Nordisk INC | $304.03 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $225.83 | 2019-2021 | |
| Lilly USA, LLC | $216.57 | 2019-2025 | Jardiance |
| Amgen INC. | $193.34 | 2019-2024 | Otezla, Repatha |
| Allergan, INC. | $130.98 | 2019 | |
| Sanofi-Aventis U.S. LLC | $118.40 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.77 | 2019-2024 | Tradjenta, Jardiance, Synjardy |
| Astellas Pharma US INC | $82.56 | 2022-2024 | Veozah, Myrbetriq |
| Novartis Pharmaceuticals Corporation | $46.02 | 2019-2020 | |
| Pulmonx Corporation | $43.25 | 2024 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $41.57 | 2025 | Caplyta |
| Organon LLC | $41.16 | 2022-2023 | Nexplanon |
| Otsuka America Pharmaceutical, INC. | $38.80 | 2023-2025 | Rexulti |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $36.98 | 2020-2021 | |
| Lundbeck LLC | $35.14 | 2025 | Rexulti |
| Exact Sciences Corporation | $34.29 | 2023-2024 | Cologuard Collection Kit |
| Ultragenyx Pharmaceutical INC. | $30.14 | 2021-2023 | |
| Pfizer INC. | $29.47 | 2020-2024 | |
| Merck Sharp & Dohme LLC | $28.53 | 2020-2022 | |
| Dexcom, INC. | $27.94 | 2021-2025 | Dexcom G6 Transmitter |
| Inspire Medical Systems, INC. | $27.67 | 2024 | Inspire |
| Eisai INC. | $26.31 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $25.48 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.44 | 2019 | |
| Sanofi Pasteur INC. | $14.74 | 2019 | |
| Ironwood Pharmaceuticals, INC | $12.90 | 2020 | |
| Genentech USA, INC. | $12.57 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $12.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Larson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.